Clinical trials: Jorge et al. demonstrated the cardiac and renal benefits of SGLT2 inhibitors in SLE/LN patients utilising electronic health records and target trial emulation to compare the outcomes of SGLT2 inhibitors with DPP-4 inhibitors in SLE patients. The gene discussed is SLC5A2; the disease is lobular neoplasia.